Paige - AI Website Builder is a company.
Key people at Paige - AI Website Builder.
Paige - AI Website Builder was founded by Mike Erman (Board member & Co-founder).
Paige - AI Website Builder was founded by Mike Erman (Board member & Co-founder).
Key people at Paige - AI Website Builder.
Paige is an AI company revolutionizing cancer diagnostics through advanced pathology tools, not a website builder as the query suggests—search results confirm it develops AI applications for diagnostic decision-making, biomarker discovery, and precision oncology.[1][2] It serves pathologists, healthcare professionals, and researchers by addressing critical challenges in cancer care, such as workload pressures, complex tissue analysis, and molecular profiling from over 25 million pathology slides across 40+ cancer types and 800+ institutions.[1][2] Paige's growth momentum includes proprietary foundation models like Virchow2 and Paige Alba™, a multi-modal co-pilot for workflows, plus partnerships with top investors and recognition in major press, enabling scalable AI deployment in 45+ countries.[1][2]
Paige emerged from a foundation in digital pathology, combining AI expertise with insights from world-renowned medical and scientific experts to tackle cancer's complexities.[2] While specific founding year and founders are not detailed in available sources, the company built its origins on the largest diverse pathology dataset—25 million slides from 350,000 patients, including 200,000 cases with outcome and genomic data—positioning it as a leader in AI for cancer care.[1][2] Early traction came from pioneering foundation models, setting standards for scale and performance, and developing clinical AI tools that gained trust from influential investors and institutions.[1][2]
Paige stands out in computational pathology through these key strengths:
Paige rides the wave of AI foundation models in healthcare, applying massive multimodal datasets to pathology—the foundational step in understanding cancer's molecular details.[1][2] Timing aligns with surging demand for precision oncology amid pathologist shortages and rising cancer cases, where AI alleviates diagnostic bottlenecks and unlocks biomarkers for targeted therapies.[1][4] Market forces like regulatory advancements and digital slide adoption favor Paige's clinically validated tools, influencing the ecosystem by accelerating third-party AI development, standardizing diagnostics across 800+ labs, and pushing boundaries in personalized medicine.[1][2]
Paige is poised to expand its foundation models and Paige Alba™ into broader precision oncology applications, potentially dominating AI-driven pathology as datasets grow and regulations evolve.[1] Trends like multimodal AI integration and global health data sharing will amplify its impact, evolving its role from diagnostic aid to ecosystem enabler for novel therapies and trials.[2] This positions Paige to redefine cancer care, directly countering the query's misconception by proving its true power lies in life-saving diagnostics, not websites.
